$17.63
0.241.38%
At close: Aug 14, 5:00 PM EST
$17.58
-0.05-0.28%
After Hours: Aug 14, 4:13 PM EST
Takeda Pharmaceutical Co Ltd
TAKNYSE
Takeda Pharmaceutical Co Earnings & Forecasts
Takeda Pharmaceutical Co (TAK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Takeda Pharmaceutical Co Guidance
Takeda Pharmaceutical Co (TAK) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided earnings per share in the range of $3.01 - $3.01, compared to a consensus EPS estimate of $1.57. Takeda Pharmaceutical Co also guided revenue in the range of $29.59B - $29.59B for the period.
Compared to prior guidance, Takeda Pharmaceutical Co maintained its EPS outlook from a previous range of $3.01 - $3.01. On the revenue side, the company maintained its revenue forecast from a prior range of $29.59B - $29.59B.
Takeda Pharmaceutical Co has issued 16 guidance updates between October 27, 2022 and July 30, 2026. During this period, the company raised its outlook 7 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.39 | $0.21 | $0.55 | $0.44 |
| Actual | $0.48 | $0.28 | $0.47 | $0.43 |
| Surprise | +23.8% | +35.2% | -13.6% | -2.27% |
| Revenue | ||||
| Estimate | $7.06B | $7.05B | $8.53B | $8.08B |
| Actual | $7.65B | $6.98B | $7.60B | $7.52B |
| Surprise | +8.42% | -1.02% | -10.9% | -6.93% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q2 '26E | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.53 | $0.52 | $0.41 | $0.48 |
| Revenue | ||||
| Consensus | $6.83B | $7.56B | — | — |
